Arvaya Healthcare Allots ₹15.49 Crore Shares for SIGPL Deal

Arvaya Healthcare Ltd has allotted 38,71,854 equity shares at ₹40 each to shareholders of Sushodha Institute of Gastroenterology Private Limited (SIGPL) under a non-cash share swap. The ₹15.49 crore preferential allotment increases Arvaya Healthcare's paid-up equity capital from ₹48.02 crore to ₹51.89 crore and advances its healthcare-platform expansion strategy.

What did Arvaya Healthcare approve for the SIGPL acquisition?

Arvaya Healthcare approved the preferential allotment of 38,71,854 equity shares to 47 non-promoter shareholders of SIGPL as consideration other than cash. The board approved the allotment at its meeting on October 24, 2026, following its earlier proposal to issue shares as part of the acquisition-related transaction.

Each share has a face value of ₹10 and was issued at ₹40, including a premium of ₹30 per share. At the issue price, the aggregate consideration is ₹15,48,74,160, or ₹15.49 crore. The company has described the arrangement as a share swap, meaning it did not involve a cash payment to the SIGPL shareholders.

The allotment follows BSE's in-principle approval for the proposed issue on October 12, 2026. Arvaya Healthcare had subsequently informed the exchange on October 17 that its board would consider the proposed allotment on October 24.

How does the share swap change Arvaya Healthcare's capital base?

The allotment raises Arvaya Healthcare's paid-up share capital by ₹3.87 crore, from ₹48.02 crore to ₹51.89 crore. The company issued 38.72 lakh new shares, increasing the number of equity shares from 4,80,21,857 to 5,18,93,711.

On the post-issue share base, the newly allotted shares represent about 7.46%. This reflects dilution for existing shareholders, while the recipients receive an equity interest in Arvaya Healthcare as consideration for the SIGPL transaction.

The issue price of ₹40 determines the disclosed transaction consideration. Separately, the supplied market-price reference of ₹116 per Arvaya Healthcare share would value the allotted shares at about ₹44.9 crore. That market-value calculation is distinct from the ₹15.49 crore issue-price consideration and does not establish SIGPL's enterprise value.

Why is SIGPL relevant to Arvaya Healthcare's strategy?

SIGPL is Sushodha Institute of Gastroenterology Private Limited, and the available disclosures position the transaction as a specialty healthcare expansion for Arvaya Healthcare. The company is building a healthcare platform spanning hospitals, diagnostics, wellness and technology after changing its name from Bijoy Hans Limited in May 2026.

The SIGPL transaction adds gastroenterology exposure to that broader healthcare direction. Based on the disclosed information, it is best characterised as a specialty-service expansion rather than confirmed vertical integration or a confirmed geographic expansion. SIGPL's location, operating capacity and regional revenue exposure have not been disclosed in the available transaction details.

Arvaya Healthcare has also pursued other restructuring and expansion measures in 2026, including fundraising initiatives and acquisition-led arrangements. The company's change in identity, control-related developments and share-swap transactions indicate a shift away from its previous corporate profile toward healthcare-related operations.

What financial details remain undisclosed in the SIGPL transaction?

The disclosed terms do not provide SIGPL's audited revenue, EBITDA, net debt, enterprise value or operating contribution. Therefore, the transaction cannot be assessed using an EV/EBITDA multiple from the information currently available.

The share issue establishes the number of Arvaya Healthcare shares issued and their stated issue price, but it does not disclose a detailed valuation bridge for SIGPL. It also does not state expected patient volumes, specialty capacity, margins or the timing of financial consolidation into Arvaya Healthcare's reported results.

These missing details are significant for assessing the acquisition's financial contribution. The disclosed share-swap consideration shows the terms of settlement, while later financial filings would be needed to show whether SIGPL contributes revenue, profitability or identifiable operating assets to Arvaya Healthcare.

How does the allotment affect investors and market participants?

For investors, the immediate measurable effect is the expansion in the equity base and the resulting 7.46% post-issue dilution. The new shares were issued at ₹40 each, while the supplied market-price reference of ₹116 indicates that the prevailing market value of the shares may differ materially from the stated issue-price consideration.

The transaction also gives the former SIGPL shareholders a direct stake in Arvaya Healthcare. Because the consideration is non-cash, Arvaya Healthcare has acquired the related interest without a stated cash outflow under this allotment. However, the effect on earnings, cash flows and margins cannot yet be quantified from the disclosures.

Market participants will need to track final listing and trading approvals for the allotted shares, along with subsequent quarterly results and regulatory filings. These disclosures may provide evidence on the transaction's accounting treatment, integration progress and any reported contribution from SIGPL.

Conclusion

Arvaya Healthcare has completed a ₹15.49 crore preferential share allotment to SIGPL shareholders, using 38.72 lakh new shares as non-cash consideration. The deal expands its paid-up capital to ₹51.89 crore, introduces measurable dilution and aligns with the company's stated move toward a broader healthcare platform.

The next disclosures to watch are final listing and trading approvals, as well as quarterly filings that may clarify SIGPL's financial contribution, operating scale and integration into Arvaya Healthcare's business. Until then, the available information supports assessment of the share issue and capital impact, but not a full valuation of SIGPL.